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Abstract
Oncogenes and tumor suppressors work in concert to regulate cell growth or death, which is a pair of antagonist factors for
regulation of tumorigenesis. Here we show promoter characteristic of tumor suppressor RASSF1A, which revealed a p53
binding site in the distal and a GC-rich region in the proximal promoter region of RASSF1A, in despite of TATA box-less. The
GC-rich region, which is ,300 bp upstream from the RASSF1A ATG, showed the strongest promoter activity in an assay of
RASSF1A-driving GFP expression. Methylation analysis of the CpG island showed that 78.57% of the GC sties were
methylated in testis tumor samples compared with methylation-less in normal testis. Hypermethylation of the GC-rich
region is associated with RASSF1A silencing in human testis tumors. In addition, electrophoretic mobility shift assay
indicated that p53 protein bound to the RASSF1A promoter. Further chromatin immunoprecipitation confirmed p53
binding to the RASSF1A. Moreover, p53 binding to the promoter down-regulated RASSF1A expression. These results
suggest that p53 protein specifically binds to the RASSF1A promoter and inhibits its expression. Our results provide new
insight into the mechanism of action of tumor suppressors and may be a starting point for development of new approaches
to cancer treatment.
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Introduction
Cancer is a leading cause of death worldwide, accounting for
7.9 million deaths in 2007 (around 13% of all deaths) (WHO 2007,
http://www.who.int/mediacentre/factsheets). Cancer is the num-
ber one killer of people in cities of Chin (25% of all deaths) based
on recent census (MOH 2008, www.moh.gov.cn). Furthermore,
deaths from cancer worldwide are projected to continue rising,
with an estimated 12 million deaths in 2030. On the cellular level,
oncogenes and tumor suppressors are key factors in controlling cell
fate. Balance between them is essential for cell growth,
differentiation and death.
Among tumor suppressors, p53 is the first and well-known
tumor-suppressor gene, which plays a central role in eliciting
cellular responses to a variety of stress signals, such as DNA
damage, through regulation of cell-cycle arrest, senescence or
apoptosis to prevent the development of cancer [1,2]. Other
cellular processes are also regulated by the p53 protein, including
autophagy [3] and exosome secretion [4]. There is evidence that
p53 protects the integrity of the genome by decreasing the levels of
intracellular reactive oxygen species; this reduces oxidative
damage and allows repair of genomic damage that might
otherwise lead to the acquisition of oncogenic mutations [5,6].
The action of p53 as a tumor suppressor is mainly due to its
transcription factor activity, which can activate or repress
downstream targets. Recently, a p53-cofactor JMY has been
identified as a transcriptional co-activator of p53 [7]. To date, 129
p53-responsive genes have been identified that encode proteins,
which mediate a wide variety of cellular stress responses [3]. The
microRNAs miR-34a and miR-34b/c are also p53 target genes
that may mediate the induction of apoptosis, cell cycle arrest and
senescence [8]. In addition, posttranslational modifications of p53,
including phosphorylation, methylation, acetylation, sumoylation,
neddylation and glycosylation, may regulate p53 transcriptional
activity and stability [9]. Recently, quaternary architecture of p53
was also revealed by structure biology studies [10]. Moreover, an
increasing variety of proposed mechanisms through which p53
functions suggests further complexity of p53 [11,12].
It is not well understood how p53 contributes to the activation
of cell death and which factors determine whether p53 induction
triggers apoptosis and/or cell cycle arrest. Elucidation of new p53
pathways, especially identification of the p53 negative regulator
MDM2 in cancer cells, has been useful in the development of
targeted therapies [13]. Further insights into the p53 pathway and
p53-mediated transcriptional control may provide a better
understanding of the molecular mechanisms underlying p53-
mediated tumor suppression.
The tumor suppressor RASSF1A (Ras association domain
family 1 isoform A) is an recently identified anti-cancer factor
whose inactivation has been implicated in the development of
many human cancers [14,15,16,17]. Loss of RASSF1A expression
stemming from RASSF1A point mutations and promoter
hypermethylation is one of the most common events in many
types of human cancers [18]. RASSF1A-knockout mice are prone
to spontaneous and induced tumorigenesis [19,20]. However, the
mechanism of RASSF1A tumor suppression and RASSF1A
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a pro-apoptotic pathway by binding to RASSF1A, which is a RAS
effector [21,22]. When bound to GTP, activated RAS regulates
cellular responses through RAS effector proteins and their
complex signal transduction cascades, such as those mediated by
the Raf serine/threonine kinases, PI3-K and RASSF1A [21,22].
Emerging evidence suggests that RASSF1A is a microtubule-
binding protein that stabilizes microtubules [23], maintains
genomic stability by modulating tubulin dynamics [24,25,26]
and regulates cell cycle arrest and mitotic progression [27,28,29].
Thus, RASSF1A is potentially an important diagnostic and
therapeutic target for the development of new anticancer drugs.
Here we present an unexpected finding of antagonism between
two tumor suppressors p53 and RASSF1A, which may reflect
inherent balance between cell death and survival this pair of tumor
suppressors regulate in cancer cells.
Materials and Methods
Cells and tissues
COS-7 and the human cervical carcinoma cell lines Siha were
obtained from China Centre for Type Culture Collection (Wuhan,
China). Testis samples were provided by Ren-Min Hospital,
Wuhan University.
Plasmids and constructs
pRASSF1A-GFP vector. To generate EGFP-tagged RASSF1A
promoter vectors (pRASSF1A-GFP), three portions (3173 bp,
1022 bp, 300 bp) of the RASSF1A promoter were amplified by
PCR and subcloned into the HindIII and KpnI sites of the pEGFP-
1 mammalian expression vector respectively (BD Biosciences
Clontech, Palo Alto, CA, USA). The primer sequences were as
follows: sense primers 59-GGAAAGCTTTGGGTCTGGAA-
TAGTTTAGGG-39 (3173 bp, (construction c), 59-GCAAAG-
CTTGCGGCTGCAGGCGCGAAG-39 (1022 bp, construction
b) and 59- GCAAAGCTTTATCTCCGCGTGGTGCTT-39
(300 bp, construction a); and antisense primer 59-CCCGGTAC-
CGGCCCGGTTGGGCCCGTGCT-39. PCR cycling conditions
were as follows: 5 min at 94uC, 35 cycles of 40 s at 94uC, 40 s at
62uC and 3 min at 72uC. All constructs were confirmed by
sequencing.
HIS–p53. The full-length p53 coding region (1179 bp) was
PCR-amplified from the pRK-7-Flag-Neo-Insert vector (a gener-
ous gift from Dr. Shu hongbin (Wuhan University), which contains
the full length of p53 coding sequence, using the p53-1 primer (59-
CAGGGATCCATGGAGGAGCCGCAGTCAG-39) and the
p53-2 primer (59-AGAGAATTCGTCTGAGTCAGGCCCTT-
CT-39). The PCR product was cloned in-frame into the
prokaryotic expression vector PET32a (Amersham Biosciences,
Uppsala, Sweden) using the BamHI and EcoRI (HIS–p53) sites.
Sodium bisulphate modification and DNA methylation
analysis
Frozen and paraffin-embedded testis tumor samples were
digested by proteinase K (0.5 mg ml
21) in Tris (10 mM,
pH 8.0), 1% SDS, 0.45% Tween 20 and EDTA (0.1 M,
pH 8.0), followed by standard phenol-chloroform extraction.
Genomic DNA was recovered after ethanol precipitation. Sodium
bisulphate modification was performed as follows: 2 mg of genomic
DNA was denatured by boiling for 10 min at 100uC and
incubated in 0.3 M NaOH for 15 min at 37uC. Cytosine residues
were sulphonated in 3.12 M sodium bisulphate (pH 5.0, Sigma, St
Louis, MO, USA) and 5 mM hydroquinone (Sigma) in a
thermocycler for 18 h at 55uC. Modified DNA was purified using
the Wizard DNA clean-up system (Promega, Madison, WI, USA).
The conversion reaction was completed by desulphonating in
0.3 M NaOH for 10 min at room temperature. The DNA was
ethanol precipitated and resuspended in 50 ml of distilled water.
Methylation-specific PCR (MSP) was then used to assess the
methylation status of the promoter regions of the RASSF1A gene.
Methylated specific primers: sense primer (59-CGA-
GAGCGCGTTTAGTTTCGTT-39) and antisense primer (59-
CGATTAAACCCGTACTTCGCTAA-39) were added to reac-
tion buffer (10 ml) containing 2 ml dNTPs (2 mM) and 1 U Taq
polymerase at 94uC for 25 s, 58uC for 20 s and 72uC for 20 s for
40 cycles. We performed semi-nested PCR using the antisense
primer 59-GCTAACAAACGCGAACCG-39. Unmethylation-spe-
cific primers were as follows: sense primer (59-GGTTTTGTGA-
GAGTGTGTTTA-39) and antisense primer (59-CACTAA-
CAAACACAAACCAAAC-39). The PCR products were purified
using a gel extraction kit (Promega), ligated into the T-easy vector
(Promega) and sequenced.
Cell culture and transfection
COS-7 and Siha cells were grown in RPMI1640 medium
containing 20% fetal bovine serum (HyClone, Logan, Utah, USA)
at 37uC with 5% CO2. Medium was replaced every other day. For
transient transfection, cells were seeded onto 24-well plates at a
density of 10
5cells/well. Constructs were transfected into COS-7
or Siha cells with Lipofectamine
TM 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. After 48 h
of incubation, cells were collected and used for analysis.
Immunohistochemistry
Serial 7-mm sections were cut with a cryostat (Leica, Bensheim,
Germany). Briefly, the sections were deparaffined in xylene and
alcohol, fixed in methanol at 220uC for 20 min and endogenous
peroxide activity in the samples was quenched using 3% hydrogen
peroxide for 20 min at room temperature. After rinsing with PBS,
nonspecific antibody binding was blocked by incubating the
sections for 20 min in goat serum. The samples were then
incubated with antibodies in a moist chamber overnight at 4uC.
The expression of RASSF1A proteins was analyzed using anti-
RASSF1A (eBioscience, CA, USA), using the SABC and DAB
visualization methods according to the manufacturer’s instructions
(Boster Company, China).
Western blots
For western blots, Siha cells were lysed in ice-cold buffer and
incubated on ice for 10 min. The samples were boiled in loading
buffer for 10 min and centrifuged at 130006g for 20 min at 4uC,
and supernatants were collected. Equal amounts of protein were
loaded into 12% polyacrylamide gels, electrophoresed and the
separated proteins were transferred to polyvinylidene difluoride
(PVDF) membranes. Nonspecific antibody binding was blocked
with 5% BSA in Tris-buffered saline (TBS) for 1 h at room
temperature. The membrane was then incubated with human
anti-p53 (1:500, Santa Cruz Biotech, CA, USA), anti-RASSF1A
(1:500), or anti-b-actin (1:1000, Santa Cruz Biotech, CA, USA)
antibody overnight at 4uC, followed by HRP-conjugated second-
ary antibody (1:50000, Santa Cruz Biotech, CA, USA) for 1 h.
The immunoreactive signal was revealed by ECL reagent (Pierce,
Rockford, USA).
Electrophoretic mobility shift assays (EMSA)
Recombinant HIS–p53 fusion protein was purified from cell
lysates by imidazole using HiTrap affinity columns according to
p53 Antagonizes RASSF1A
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to testify that p53 is a potential transcription factor of RASSF1A
promoter, DNA binding assay was employed. For the EMSA
assay, two probes were used: a wild type probe and a mutant
probe. The wild type probe sequence is 59-TTCCGGGTCA-
GGGCCTGGCAGGAAGGGAGAT-39, and that of the mutant
probe is 59-TTCCGGGTTGAAGCCTGGCAGGAAGGGA-
GAT-39. Double-stranded probes were made by annealing
oligonucleotides into double strands and labelled with T4
polynucleotide kinase (Gel Shift Assay Core System; Promega)
in the presence of [c-32P]dATP. Unincorporated nucleotides
were removed by chromatography through Sephadex G-25 resin.
The concentrations for the DNA binding reaction were 1.5 mM
for protein and 40 nM for DNA. The binding reaction was
carried out at room temperature for 1 h according to the
manufacturer’s protocol (Gel Shift Assay Core System; Promega)
before loading onto a 6% polyacrylamide gel. Complexes were
separated by native gel electrophoresis (10 V/cm at 4uC with
0.56TBE buffer). The antibody or competitor oligonucleotide
(the single stranded oligonucleotide in 20-fold molar excess) was
added at the start of the incubation for the supershift and
competition experiments.
Chromatin immunoprecipitation (ChIP)
Siha cells were cross-linked in 1% formaldehyde to cross-link
endogenous proteins and DNA. Samples of sonicated chromatin
were immunoprecipitated with no antibody (beads only), pre-
immuno IgG (IgG), anti-p53 antibody, and Protein G PLUS-
Agarose (Santa Cruz Biotech, CA, USA) was added to the
samples. DNA isolated from the immunoprecipitated complex
was amplified by PCR with primers flanking the p53 binding
site (a region of 147 bp corresponding to the 22799 to 22653of
the RASSF1A promoter). The primer sequences are: sense primer
59-GCCTCCATCATCAACCTCT-39 and the antisense primer
59-GAGGGAAACTTTCTGTGTC-39. The amplified PCR
fragments were analysed on 2% agarose gel. A region of
192 bp flanking intron 1 and exon 2 of the RASSF1A was
amplified as a control with primers: sense: 59-TGAGGTAACC-
Figure 1. Promoter activity and methylation analysis of RASSF1A in human testis cancer. A, RASSF1A promoter activity by GFP expression
under the control of different length of RASSF1A promoter segments. A predicted p53 binding site in RASSF1A promoter (22718 bp) was showed in
the construction c. B, CpG island prediction of RASSF1A by software MethPrimer online (http://www.urogene.org/methprimer/). Predicted CpG island
is indicated by blue color. C, Representative results of the methylation-sensitive PCR (MSP) analysis of RASSF1A in both seminoma and nonseminoma.
M, MSP PCR; U, unmethylation-sensitive PCR. D, DNA methylation status of individual CpG sites by sodium bisulfite sequencing analysis. Black and
white circles represent methylated and unmethylated CpGs respectively.
doi:10.1371/journal.pone.0017017.g001
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AGGCAGA-39.
Results
Hypermethylation of the GC-rich region of the RASSF1A
promoter is associated with RASSF1A silencing in human
testis tumors
To get insight into regulation of RASSF1A expression, we first
analyzed its promoter characteristic, which revealed a p53 binding
site and a GC-rich region. The GC-rich region, which is ,300 bp
upstream from the RASSF1A ATG, showed the strongest promoter
activity in an assay that tested the ability of promoter regions to
drive GFP expression (Fig. 1A). RASSF1A lacks a TATA box in its
promoter, and the GC-rich region seems essential for transcription
initiation by the RNA polymerase II complex; this is consistent
with recent findings that transcription over short distances (250
nucleotides upstream) is common for active promoters [30]. This
region is also within the CpG island of the RASSF1A promoter
(Fig. 1B). Further bisulphite sequencing of the RASSF1A CpG
island showed that 78.57% of the GC sties (11/14) were
methylated in testis tumors in both seminoma and nonseminoma
samples while no methylation was detected in normal testis
(Fig. 1C, D). Immunohistochemical analysis revealed that high
methylation resulted in very weak expression of RASSF1A in testis
tumor samples (Fig. 2B); while RASSF1A was expressed in both
the nuclei and cytoplasm of spermatogonia, spermatocytes, Sertoli
cells and Leydig cells in normal testis (Fig. 2A).
p53 binds to RASSF1A promoter
As a predicted p53-binding site exists in the RASSF1A
promoter (at 22718 bp), although lack of methylation CpG site
in the binding site, further functional test for the binding site using
gel-shift assay showed that His–p53 specifically and efficiently
bound to RASSF1A (Fig. 3A). The specific interaction was
confirmed by adding the p53 antibody into the binding reaction,
resulting in a supershift band (antibody/p53/RASSF1A) (Fig. 3A,
lane 2). Furthermore, a mutant RASSF1A probe decreased the
formation of the p53/RASSF1A complex. Further test in vivo of
p53 binding to the RASSF1A promoter using Chromatin
Immunoprecipitation (ChIP) assay confirmed p53 binding to the
RASSF1A (Fig. 3B). These results indicated that the p53 protein
specifically binds to the RASSF1A promoter.
p53 binding to RASSF1A promoter downregulates
RASSF1A expression
We then examined the effect of p53 binding on RASSF1A
expression using a RASSF1A promoter-EGFP expression reporter
construct (pRASSF1A-EGFP). When p53 and pRASSF1A-EGFP
were co-transfected into COS-7 cells, expression of the reporter
EGFP was significantly inhibited in a dose-dependent manner,
reaching saturation when 40 ng of the p53 vector was transfected
(Fig. 4A). Fluorescent microscopy analysis showed directly that
p53 remarkably decreased expression of RASSF1A-GFP (Fig. 4B).
Further, when p53 was overexpressed in endogenous RASSF1A-
expressing Siha cells, RASSF1A protein expression was markedly
decreased (Fig. 4C). These results indicated that p53 protein not
only specifically binds the RASSF1A promoter but also efficiently
downregulates RASSF1A expression.
Discussion
Tumor suppressors restrict the proliferation of abnormal or
cancerous cells by regulating cell-cycle arrest, senescence or
apoptosis to prevent the development of cancer. Loss of a single
tumor suppressor is sufficient for initiation of tumorigenesis.
Tumor suppressors can also act together using a common
pathway to regulate cell growth [31]. However, it remains unclear
whether or how tumor suppressors regulate each other against
tumorigenesis.
In this study, we showed that the p53 tumor suppressor inhibits
RASSF1A by binding to its promoter. The crosstalk of tumor
suppressors p53 and RASSF1A reveals a new pathway for
cancerous cells to regulate cell death. This could be an inherent
feedback loop for cell survival when stress or damage is present.
When p53 was upregulated, we observed marked inhibition of
RASSF1A expression, due to p53 binding to the RASSF1A
promoter. Interestingly, recent reports showed that another
member of the RASSF family, RASSF5, regulates growth
inhibition via promoting p53 nuclear localization [32], which
may provide a clew for a common link between RASSF and p53
for cell death regulation.
Physiologically, the apoptotic response reflects the cumulative or
integrative action of numerous p53-induced signals. On the one
hand, p53 regulates the cell cycle and apoptosis by pathways such
as MDM2-p53 and microRNAs-p53, or by inducing the
expression of numerous apoptotic genes that contribute to the
Figure 2. Immunohistochemical staining of RASSF1A in human testis cancer. Normal testis sample (A) and testis tumor with methylated
RASSF1A (B). Normal testis section stained positively for RASSF1A. RASSF1A was mainly expressed in cytoplasm of the spermatogonia (SG),
spermatocytes (SC), Sertoli cells (Sn) and Leydig cells (LC) of normal testis, while seminoma sample with methylated RASSF1A showed weak staining.
Nuclei were stained with Hematoxlin.
doi:10.1371/journal.pone.0017017.g002
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pathways and by affecting the efficiency of survival signalling. On
the other hand, and of particular note, the p53-RASSF1A
pathway described here may attenuate cell damage by silencing
the RASSF1A tumor suppressor. This reflects the inherent balance
between the death of cancerous cells and cell survival, a balance
regulated by this pair of tumor suppressors. The ability to engage
apoptotic pathways via several routes is likely to be important for
the activity of the tumor-suppressor p53. These findings add a new
layer of complexity to what is known about the p53 network. In
addition, hypermethylation of the proximal promoter region of
RASSF1A, which we detected in testis tumors, is another common
event for cancer cells to escape from apoptosis. Thus we conclude
that the p53-RASSF1A pathway, at least along with hypermethy-
lation (in the proximal promoter region of RASSF1) and point
mutations, contribute to RASSF1A silencing in cancerous cells.
These results add to the known complexity of the p53 network,
but also provide new insights into the p53-RASSF1A pathway and
highlight the potential importance of crosstalk among tumor
suppressors in the prophylaxis and treatment of cancer inherent
Figure 3. p53 protein binds to the RASSF1A promoter. A, EMSA
analysis of p53 binding to the RASSF1A promoter. WT, the wild type p53
binding site probe from human RASSF1A promoter; Mut, mutant p53
binding site probe; ds, two complementary oligonucleotide probes; ss,
single stranded probe. The supershift band in lane 2 contains the anti-
p53/wt DNA/p53 protein complex. Complexes were separated by native
gel electrophoresis. Mutant sequence was showed in lower panel. B,
ChIP assay of p53 binding to the RASSF1A promoter in Siha cells.
Samples of sonicated chromatin from Siha cells cross-linked in 1%
formaldehyde were immunoprecipitated with anti-p53 antibody,
preimmuno IgG (IgG) and no antibody (beads only). DNA isolated from
immunoprecipitated material was amplified by PCR with primers to
amplify the 147 bp RASSF1A promoter sequences flanking the p53
binding site (22799 bp to 22653 bp). A region of 192 bp flanking
intron 1 and exon 2 of the RASSF1A was amplified as a control. Input
lanes represent sonicated chromatin samples as positive control. The
amplified PCR fragments were analysed on 2% agarose gel.
doi:10.1371/journal.pone.0017017.g003
Figure 4. Down-regulation of RASSF1A by p53. A, RASSF1A
promoter activity was inhibited by p53 protein with a dose dependent
manner. pRASSF1A-GFP (construction c in Fig. 1) was co-transfected
with different concentration of CMV-p53 into COS-7 cells, and
transfected cells were analyzed by the flow cytometry. B, pRASSF1A-
GFP was transfected into COS-7 cells (a) or co-transfected with p53 (b),
and images were taken under fluorescent microscopy. p53 remarkably
decreased expression of RASSF1A-GFP. GFP was mainly expressed in the
cytoplasm. Nuclei were stained with Hoechst. C, Overexpression of p53
in Siha cells decreased RASSF1A protein levels, revealed by Western blot
analysis of RASSF1A and p53 expression using anti-RASSF1A or p53
antibody after transfection of the p53 expression plasmid into Siha cells.
Lysates of non-transfected cells and cells transfected with the pcDNA3
vector were used as controls. b-actin was used as an internal control.
Molecular weights of the proteins are shown on the right.
doi:10.1371/journal.pone.0017017.g004
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strategies for improved cancer therapy using tumor suppressors as
targets. Further analysis of the p53-RASSF1A pathway should
provide a better understanding of the molecular mechanisms of
tumor suppression.
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